AC Immune WKN: A2AR5F ISIN: CH0329023102 Kürzel: IMR

Kurs zur AC IMMUNE Aktie
3,01 EUR
±0,00 %±0,00
28. May, 12:21:59 Uhr, Lang & Schwarz
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker
6
66HK, Gestern 23:31
Ist ja schade dass ac den heutigen aufschwung nicht mitgenommen hat
6
66HK, 19. Mai 13:37
Also an andere Unternehmen verteilt haben die es.
6
66HK, 19. Mai 13:35
This prospectus supplement relates to periodic offers and sales by the Selling Shareholders listed below, and their pledgees, assignees, transferees and other successors in interest, of up to 18,041,000 common shares. dievini Hopp BioTech holding GmbH&Co KG (“dievini”) previously registered the resale of its shares on a registration statement on Form F-3 that was declared effective on September 7, 2018. As part of an internal reorganization, dievini has distributed certain common shares of the Company to affiliated entities listed in the table below. The following table provides information regarding the Selling Shareholders’ beneficial ownership of our common shares as of May 18, 2022. Beneficial ownership is determined in accordance with the rules of the Commission and includes any common shares as to which a person has sole or shared voting power or investment power and any common shares which the person has the right to acquire within 60 days after May 18, 2022 through the exercise of any option, warrant or right or through the conversion of any convertible security. As described in the footnote to the table below, we believe, based on information furnished to us, that the Selling Shareholders in this table have shared voting and investment power with respect to the shares indicated as beneficially owned. The percentage of beneficial ownership is based upon 83,552,294 common shares issued and outstanding as of the date of this prospectus supplement
Henry1966
Henry1966, 18. Mai 2:22
Diese Meilensteinzahlungen bringen uns hoffentlich in 3 bis 5 Jahren auch was😉
Henry1966
Henry1966, 18. Mai 2:21
Was wichtig erscheint….. About AC Immune SA AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.
Henry1966
Henry1966, 18. Mai 2:20
An dieser Stelle möchte ich die Arbeit von Frau Dr. Andrea Pfeifer auch würdigen. Herzliche Gratulation aus Südamerika.
Henry1966
Henry1966, 18. Mai 2:15
Es gibt da noch News, hatte dies heut im Postfach….. https://ir.acimmune.com/news-releases/news-release-details/ac-immune-ceo-andrea-pfeifer-receives-aenne-burda-award
Henry1966
Henry1966, 18. Mai 1:04
Locker vom Hocker Kein Stress
Kommentare
1 AC IMMUNE Hauptdiskussion
Kursdetails
Geld (bid) 2,98 (3.987)
Brief (ask/offer) 3,04 (3.987)
Spread 1,97
Geh. Stück 0
Eröffnung 3,01
Vortag 3,01
Tageshoch 3,01
Tagestief 3,01
52W Hoch 10,93
52W Tief 2,30
Tagesvolumen
in EUR gehandelt 4.270 Stk
in USD gehandelt 47.542 Stk
Gesamt 51.812 Stk
Anzeige
Smartbroker
Der Broker von Deutschlands größter Finanzcommunity
Geld/Brief Kurse
Börse Geld Brief Zeit Volumen Kurs
Frankfurt 2,86 2,94 1653632009 27. May 2,98 EUR
Berlin 2,87 3,11 1653681147 27. May 3,01 EUR
Düsseldorf 2,95 3,02 1653672691 27. May 2,99 EUR
München 2,92 3,05 1653680723 27. May 70 Stk 2,98 EUR
Stuttgart 2,94 3,03 1653679797 27. May 2,96 EUR
Nasdaq 3,19 3,22 1653696000 02:00 47.442 Stk 3,22 USD
AMEX 1653681720 27. May 100 Stk 2,47 USD
Tradegate 2,91 3,06 1653683224 27. May 4.200 Stk 2,99 EUR
Lang & Schwarz 2,98 3,04 1653733319 12:21 3,01 EUR
London 1652374639 12. May 2,67 USD
Gettex 2,92 3,05 1653680581 27. May 3,02 EUR
Baader Bank 2,92 3,05 1653681586 27. May 2,99 EUR
TTMzero RT 1653636361 27. May 3,02 EUR
ges. 51.812 Stk
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR
267,7 Mio.
Anzahl der Aktien
89,6 Mio.
Grundlegende Daten zur AC IMMUNE Aktie
Finanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
KUV - - - - - - -
Ergebnis je Aktie (bereinigt) - - - - - - -
Cashflow - - - - - - -
Eigenkapitalquote - - - - - - -
Verschuldungsgrad - - - - - - -
Eigenkapitalrendite - - - - - - -
Gesamtkapitalrendite - - - - - - -
EBITDA - - - - - - -
EBIT - - - - - - -
Fundamentaldaten 2018 2019 2020 2021 2022e 2023e 2024e
KCV - - - - - - -
Dividendenrendite - - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - - -
Dividende je Aktie - - - - - - -
Bilanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
Netto-Provisionsüberschuss - - - - - - -
Umsatzerlöse - - - - - - -
Ergebnis vor Steuern - - - - - - -
Steuern - - - - - - -
Ausschüttungssumme - - - - - - -
Nettoverzinsung - - - - - - -
Zinsertrag - - - - - - -
Gesamtertrag - - - - - - -
BörsennewsApp
BörsennewsApp im Google Play Store
BörsennewsApp im Apple Store

© 2022 börsennews.de

Daten und Kurse:

TTMzero RealTime

SIX Financial Information SIX Financial Information

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.